NanoViricides Inc. (NNVC)

[changes_iv]

WEST HAVEN, CONNECTICUT -- Monday, November 4th, 2013 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that theDengueCide evaluation contract has been renewed with Dr. Eva Harris’ Laboratory at the University of California, Berkeley, School of Public Health, Division of Infectious Diseases and Vaccinology.

Dr. Harris is one of the world’s leading experts in dengue. This contract renewal will allow the Company to continue its drug development program for the treatment of dengue.

www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20Renewal%20of%20DengueCide%E2%84%A2%20Evaluation%20Contract%20with%20the%20Professor%20Eva%20Harris%20Laboratory%20at%20the%20University%20of%20California,%20Berkeley.html

I am sure we are stockpiling FluCide for the full tox study and if we stop is to meet our contractual obligations and to make sure that after FluCide we build momentum.

We have a contractual obligation with Berkeley Laboratory at the University of California. It also represents the next step after FluCide. It establishes the technology of our small company, clearly indicating that they are truly broad-spectrum. As a drug with Orphan Designation in the U.S. and Europe it represents another life-saving drug with a potential prize north of US $200 million.

"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.

Once we get thru FluCide's (4) Phases of the Clinical Trials in Australia, all (4) in a few short months, we move on to DengueCide for (6) months and then to the next drug in the pipeline. We have months to go and no time to sleep!

We have probably met all immediate contractual obligations and we are back producing FluCide and quite soon we will start the non-stop full tox study as Dr. E. Seymour has stated, quite soon.

Without much ado, do you really believe the "good doctors" are going to miss this opportunity, risk it all? I believe they had a good plan with time allocated for slowdowns. Of course, it is all speculation on my part.

I personally expect the pps to be north of US $1000 pps after DengueCide because, once again, the "LEGO-like pieces" technology and the broad spectrum characteristic is by then well established. Approximately every (6) months a new drug in the pipeline is brought to market. In my view we start rocketing to the market stratosphere after DengueCide.

DaysOnTheBeach speculated possibly US $4000 pps? I don't know if he is taking into account CommonColdCides (CCC) or RhinovirusCide, potentially a US $120 billion worldwide market.

I know you are saying opinion, speculation on my part and others that believe on the technology. What else is there? I am an outsider reading PRs, NNVC forum posts, trying to better understand it all.

Vaccines for animals will be replaced by the effective, fast acting nanoviricides. And why not plants and tree viruses as well. Who are we going to partner with on that endeavour? And the speculation goes on and on!
=================================================

Economics professor Josh Hall describes how greater economic freedom leads to higher incomes and more economic development over time. When governments allow citizens the freedom to trade, own property, create businesses, and contract with others, the income of average citizens grows over time. This effect can be observed internationally when comparing countries, as well as domestically when comparing states in the US.